Major depressive disorder

InvestmentPitch Media Video Discusses MindBio Therapeutics’ Receipt of Initial Shipment of 1,000,000 Microdoses of LSD for Phase 2 Clinical Trials for Depression

Retrieved on: 
Wednesday, May 31, 2023
Volunteering, GMP, National Alliance, Male, Microdosing, CSE, Depression, Canadian Securities Exchange, Good manufacturing practice, Suicide, Clinical Trials Registry – India, FSE, Social connection, LSD, Government, Placebo, Creativity, National Alliance on Mental Illness, DSM-IV codes, 2011 Canadian government hackings, Patient, Mental disorder, Happiness, Ethics, Therapy, Death, News, Science and technology in Asia, Major depressive disorder, Pharmaceutical industry

VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, received its initial microdoses of LSD.

Key Points: 
  • VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, received its initial microdoses of LSD.
  • This LSD will be used to create a novel sublingual formulation for LSD microdosing.
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • The video is available for viewing on “ InvestmentPitch ” and on “ YouTube ”.

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Tuesday, May 30, 2023
Presenteeism, Major depressive disorder, Central nervous system, Solriamfetol, Obstructive sleep apnea, Somnolence, State University of New York Upstate Medical University, EDS, Narcolepsy, Disability, Functional disorder, OSA, CNS, ASCP, Drug, MDD, MD, Patient, Domain, Ontario Prehospital Advanced Life Support Studies, Randomness, Medication discontinuation, Annual general meeting, Magnetic resonance, United, Therapy, SHARP, Society, Dextromethorphan/bupropion, Cognitive deficit, Pharmaceutical industry, Medical device, Apnea

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami. The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD). The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).

Key Points: 
  • NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami.
  • The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD).
  • The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA).
  • “MDD is the leading cause of disability worldwide and improvement in functioning is critically important to people with MDD.

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention

Retrieved on: 
Wednesday, May 31, 2023
Cognition, Drug development, Depression, Cognitive deficit, Phase II, Deficit spending, Hope, ASX, EST, Attention, CMO, MADRS, ACW, Alzheimer's disease, Data analysis, MDD, Patient, Convention center, Boston Convention and Exhibition Center, Major depressive disorder, Medical device, Medical imaging, Pharmaceutical industry

SYDNEY, May 31, 2023 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay and CMO Dr Dana Hilt will present at the BIO International Convention, to be held at the Boston Convention & Exhibition Center from June 5-8, 2023. The Actinogen presentation is scheduled at 4pm EST Monday June 5, in Room 403.   

Key Points: 
  • The Actinogen presentation is scheduled at 4pm EST Monday June 5, in Room 403.
  • Dr Gourlay and Dr Hilt will be discussing progress made with the Company's two ongoing Phase 2 trials:
    This Phase 2a, proof-of-concept trial commenced in December 2022 and will treat 160 patients with Major Depressive Disorder (MDD) who also have cognitive impairment.
  • Cognitive impairment is common in MDD and currently there are no anti-depressant drugs approved for its treatment, although some companies have reported trials to assess effects of their anti-depressants on cognition.
  • "Actinogen is at an important juncture in the world of drug development with its promising oral therapy Xanamem.

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

Retrieved on: 
Wednesday, May 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PK, Human, Inc., PD, Part, Journal of Environmental Science and Health, Part C, NEO, Patient, Generalized anxiety disorder, NYSE, Major depressive disorder, Pharmaceutical industry

As expected, robust psychedelic effects were seen within two minutes, reaching a peak at about thirteen minutes.

Key Points: 
  • As expected, robust psychedelic effects were seen within two minutes, reaching a peak at about thirteen minutes.
  • “The first-in-human dosing of CYB004 represents an enormous step forward in the clinical advancement of our program evaluating this innovative compound for the potential treatment of Generalized Anxiety Disorder,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • “The inclusion of CYB004 dosing in our Phase 1 trial affords us the opportunity to better understand the PK/PD profile of CYB004 and validate the advantages of this proprietary molecule in humans earlier than expected.
  • The Company anticipates a topline data readout from the Phase 1 trial in the third quarter of calendar year 2023.

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting

Retrieved on: 
Wednesday, May 24, 2023
Safety, Magnetic resonance, Patient, CORAL, Central nervous system, Standard, Randomized controlled trial, Therapy, Society, Major depressive disorder, CNS, Annual general meeting, Pharmaceutical industry

CORAL GABLES, Fla., May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting.

Key Points: 
  • CORAL GABLES, Fla., May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in-person in two late-breaking poster presentations at the American Society of Clinical Psychopharmacology 2023 Annual Meeting.
  • The conference is being held Tuesday, May 30 – Friday, June 2, 2023, in Miami, FL.
  • Details of the poster presentations are as follows:
    Title: Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
    The posters will be available at https://www.relmada.com/science/data-and-publications at the conclusion of the conference.
  • Further information on the conference can be found here: https://ascpp.org/ascp-meetings/ascp-annual-meeting/ .

Bragar Eagel & Squire, P.C. Is Investigating Relmada, and Sanmina and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, May 20, 2023
P.C, Depression, Life, SANM, Bank statement, Audit committee, GAAP, MADRS, Report, NYSE, MDD, News, Major depressive disorder, Pharmaceutical industry, Cryptocurrency, Audit, Sanmina Corporation

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), and Sanmina Corporation (NASDAQ: SANM).

Key Points: 
  • NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (NYSE: RLMD), and Sanmina Corporation (NASDAQ: SANM).
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Additional information about each case can be found at the link provided.
  • Sanmina also disclosed that "[t]he associated interim periods for the Affected Periods were also impacted.

Bragar Eagel & Squire, P.C. Is Investigating Fox, Cutera, and Relmada and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, May 15, 2023
Fox News, Defamation, P.C, FOX, Depression, Major depressive disorder, Fox, Trump, Form 10-K, Smartmatic, MADRS, FOXA, MDD, Security (finance), NYSE, News, Murdoch family, Delaware Superior Court, Listing Rules, Dominion Voting Systems, Fox Corporation, Cryptocurrency, Audit, Dominion

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • In November and December of 2020, Fox News broadcasted reports stating that the U.S. election was rigged.
  • Fox News specifically called out Smartmatic and Dominion Voting Systems, voting technology and software companies, for their alleged involvement in rigging the election.
  • Both companies have sued Fox for defamation and other claims based on defendants' actions.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Relmada Therapeutics, Inc. (RLMD) Investigation

Retrieved on: 
Thursday, May 11, 2023
Class Action Lawsuit, Professional Services, Legal, Depression, MDD, News, MADRS, Major depressive disorder, Pharmaceutical industry

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ: RLMD).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Relmada Therapeutics, Inc. (“Relmada” or “the Company”) (NASDAQ: RLMD).
  • Investors who purchased Relmada securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/rlmd .
  • If you are aware of any facts relating to this investigation or purchased Relmada shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/rlmd .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

RELMADA ALERT: Bragar Eagel & Squire, P.C. is Investigating Relmada Therapeutics, Inc. on Behalf of Relmada Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, May 10, 2023
Class Action Lawsuit, Professional Services, Legal, P.C, Depression, Telephone, Jeanne Eagels, MADRS, MDD, News, NYSE, Major depressive disorder, Pharmaceutical industry

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) on behalf of Relmada stockholders.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Relmada Therapeutics, Inc. (“Relmada” or the “Company”) (NYSE: RLMD) on behalf of Relmada stockholders.
  • Our investigation concerns whether Relmada has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a monotherapy for Major Depressive Disorder (MDD).
  • Specifically, the REL-1017 treatment showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for placebo, a higher-than-expected placebo response.

Neuronetics Reports Record First Quarter 2023 Financial and Operating Results

Retrieved on: 
Tuesday, May 9, 2023
Borrowing base, Accountability Act, Major depressive disorder, Wi-Fi, Network, TMS, Internet, Blue Cross Blue Shield Association, Telephone, BCBS, Policy, SOFR, Health policy, Government, Medicare, Neuronetics, UnitedHealth Group, Health Insurance Portability and Accountability Act, EBITDA, MDD, Patient, Practitioner, Webcast, FDA, Mental health, Success, Cryptocurrency, Video game, Mobile phone

In the first quarter of 2023, U.S. treatment session revenue per active site was approximately $9,700 compared to approximately $9,874 in the first quarter of 2022.

Key Points: 
  • In the first quarter of 2023, U.S. treatment session revenue per active site was approximately $9,700 compared to approximately $9,874 in the first quarter of 2022.
  • Gross margin for the first quarter of 2023 was 73.3%, a decrease of approximately 210 basis points from the first quarter of 2022 gross margin of 75.4%.
  • Operating expenses during the first quarter of 2023 were $21.3 million, a marginal increase of $0.5 million, or 2%, compared to $20.8 million in the first quarter of 2022.
  • EBITDA for the first quarter of 2023 was $(8.8) million as compared to the first quarter of 2022 EBITDA of $(9.5) million.